Dato Dr Kim Tan is the Chairman of SpringHill Management, a private fund management company specialising in biotech and social venture capital investments. He is a partner of several social impact funds including Inqo Investments (South Africa), Springhill Equity Partners (US), Novastar Ventures (Kenya) and Garden Impact Investment (Singapore). He is the co-founder of the Transformational Business Network and is on the advisory boards of the John Templeton Foundation, Johnson & Johnson Citizenship Trust, PovertyCure and Sustainia. He was the founder chairman of NCI Cancer Hospital (Malaysia) and the inventor of sheep monoclonal antibodies. He is a Pro-Chancellor of Surrey University, a board member of the APEC Life Science Innovation Forum, the Centre for Enterprise, Markets & Ethics (Oxford) and a Fellow of the Royal Society of Medicine (UK). He is the co-author of ‘Fighting Poverty through Enterprise’ and ‘Social Impact Investing: New agenda in fighting poverty’.